BahrainTuberculosis profile
Population  2016 1.4 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.56 (0.51–0.62)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.1 (0.07–0.14)
Incidence  (includes HIV+TB) 0.18 (0.15–0.2) 12 (11–14)
Incidence (HIV+TB only) <0.01 (<0.01–0.01) 0.59 (0.49–0.69)
Incidence (MDR/RR-TB)** <0.01 (0–0.01) 0.3 (0–0.69)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females <0.01 (<0.01–0.01) 0.043 (0.037–0.05) 0.052 (0.044–0.06)
Males <0.01 (<0.01–0.011) 0.12 (0.099–0.13) 0.13 (0.11–0.14)
Total 0.018 (0.015–0.021) 0.16 (0.14–0.18) 0.18 (0.15–0.2)
TB case notifications, 2016  
Total cases notified 154
Total new and relapse 154
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 3%
          - % pulmonary 64%
          - % bacteriologically confirmed among pulmonary 89%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.05 (0.05–0.06)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 4 100%
          - on antiretroviral therapy 1 25%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  3
(0–6)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.28–8.1) 50% (1.3–99)  
% notified tested for rifampicin resistance 56% 0% 86
MDR/RR-TB cases tested for resistance to second-line drugs   2
Laboratory-confirmed cases MDR/RR-TB: 2, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 1, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2015    
Previously treated cases registered in 2015    
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data